Tirzepatide vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | Gonadorelin |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |